141 related articles for article (PubMed ID: 28748017)
1. [Factors associated with immunovirologic dissociation in HIV-1-infected patients under highly active antiretroviral therapy in the Ambulatory Treatment Center (ATC) in Dakar].
Kà D; Manga NM; Ngom-Guéye NF; Ndiaga D; Diop M; Cisse-Diallo VMP; Diallo-Mbaye K; Lakhe NA; Fortès-Déguenonvo L; Ndour CT; Diop-Nyafouna SA; Seydi M
Pan Afr Med J; 2017; 27():16. PubMed ID: 28748017
[TBL] [Abstract][Full Text] [Related]
2. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
[TBL] [Abstract][Full Text] [Related]
3. Initial suboptimal CD4 reconstitution with antiretroviral therapy despite full viral suppression in a cohort of HIV-infected patients in Senegal.
Batista G; Buvé A; Ngom Gueye NF; Manga NM; Diop MN; Ndiaye K; Thiam A; Ly F; Diallo A; Ndour CT; Seydi M
Med Mal Infect; 2015 Jun; 45(6):199-206. PubMed ID: 25907261
[TBL] [Abstract][Full Text] [Related]
4. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.
Nanteza MW; Mayanja-Kizza H; Charlebois E; Srikantiah P; Lin R; Mupere E; Mugyenyi P; Boom WH; Mugerwa RD; Havlir DV; Whalen CC
J Infect Dis; 2011 Sep; 204(6):884-92. PubMed ID: 21849285
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with paradoxical immune response to antiretroviral therapy in HIV infected patients: a case control study.
Casotti JA; Passos LN; Oliveira FJ; Cerutti C
BMC Infect Dis; 2011 Nov; 11():306. PubMed ID: 22047047
[TBL] [Abstract][Full Text] [Related]
7. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
8. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy.
Jevtović DJ; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2005 Mar; 6(2):140-3. PubMed ID: 15807721
[TBL] [Abstract][Full Text] [Related]
9. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
10. Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.
Porter BO; Anthony KB; Shen J; Hahn B; Keh CE; Maldarelli F; Blackwelder WC; Lane HC; Kovacs JA; Davey RT; Sereti I
AIDS; 2009 Jan; 23(2):203-12. PubMed ID: 19098490
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil.
Grinsztejn B; Veloso VG; Pilotto JH; Campos DP; Keruly JC; Moore RD
J Acquir Immune Defic Syndr; 2007 Aug; 45(5):515-20. PubMed ID: 17558332
[TBL] [Abstract][Full Text] [Related]
12. The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment.
Pantazis N; Touloumi G; Meyer L; Olson A; Costagliola D; Kelleher AD; Lutsar I; Chaix ML; Fisher M; Moreno S; Porter K;
AIDS; 2016 Mar; 30(6):879-88. PubMed ID: 26636925
[TBL] [Abstract][Full Text] [Related]
13. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals.
Greenbaum AH; Wilson LE; Keruly JC; Moore RD; Gebo KA
AIDS; 2008 Nov; 22(17):2331-9. PubMed ID: 18981772
[TBL] [Abstract][Full Text] [Related]
14. Immunovirologic characteristics of human immunodeficiency virus-infected patients consisting mainly of injecting drug users on highly active antiretroviral treatment with prolonged virologic failure.
Vallejo A; Ruiz-Mateos E; Molina-Pinelo S; Soriano-Sarabia N; de Felipe B; Gutierrez S; Sánchez-Quijano A; Lissen E; Leal M
Viral Immunol; 2006; 19(4):759-67. PubMed ID: 17201671
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
Sterling TR; Chaisson RE; Moore RD
AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
[TBL] [Abstract][Full Text] [Related]
16. Rapid suppression of HIV-RNA is associated with improved control of immune activation in Mozambican adults initiating antiretroviral therapy with low CD4 counts.
Almeida JM; Letang E; Nhampossa T; Ayala E; David C; Menendez C; Gascon J; Alonso P; Naniche D
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):705-11. PubMed ID: 21091388
[TBL] [Abstract][Full Text] [Related]
17. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.
Karo B; Krause G; Castell S; Kollan C; Hamouda O; Haas W;
BMC Infect Dis; 2017 Jul; 17(1):517. PubMed ID: 28743248
[TBL] [Abstract][Full Text] [Related]
18. CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.
Li X; Margolick JB; Jamieson BD; Rinaldo CR; Phair JP; Jacobson LP
J Acquir Immune Defic Syndr; 2011 Aug; 57(5):421-8. PubMed ID: 21602699
[TBL] [Abstract][Full Text] [Related]
19. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
[TBL] [Abstract][Full Text] [Related]
20. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
Miró JM; Manzardo C; Pich J; Domingo P; Ferrer E; Arribas JR; Ribera E; Arrizabalaga J; Loncá M; Cruceta A; de Lazzari E; Fuster M; Podzamczer D; Plana M; Gatell JM;
AIDS Res Hum Retroviruses; 2010 Jul; 26(7):747-57. PubMed ID: 20624069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
